PONTE VEDRA, Fla., April 11, 2024  /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, will present at Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET. The formal presentation will feature a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 11, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No .) 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 (Address of ...

tecarfarin产品信息 - tecarfarin是一种晚期新型口服可逆抗凝剂，用于预防心脏病发作、中风和因血栓导致死亡的罕见心血管疾病患者[15] - tecarfarin获得了美国FDA颁发的孤儿药物认定，用于ESKD和Afib患者预防心源性全身性血栓栓塞[21] - tecarfarin的发展重点是在无法通过华法林获得可靠慢性抗凝的罕见心血管疾病患者群体，包括LVAD患者、ESKD和Afib患者以及具有血栓性抗磷脂综合征的患者[19] - tecarfarin的IND申请旨在将其作为一种替代VKA，具有对AFib、DVT、PE等广泛适应症的优越疗效和安全性[17] tecarfarin临床试验和效果 - Tecarfarin在11项人类临床试验中表现良好，只有1.6%的受试者出现重大出血[25] - Tecarfarin的代谢途径与华法林不同，且在临床研究中表现出更可靠的抗凝效果[26] - Tecarfarin设计避开CYP450代谢途径，避免与其他药物相互作用导致抗凝水平不稳定[28] - Tecarfarin的代谢途径不同于CYP450途径，可能通过大容量和非饱和组织酯酶途径实现更可靠的抗凝效果[29] tecarfarin市场前景和发展计划 - 公司目标是建立一个以罕见心血管疾病产品候选品为基础的生物制药公司[38] - 公司计划在2025年启动关键三期临床试验，寻求FDA批准Tecarfarin用于抗凝治疗[38] - 公司计划通过补充NDA扩大Tecarfarin的适应症范围，包括LVADs和APS患者的治疗[39] - 公司计划与合作伙伴合作或收购临床阶段心血管产品，以增强当前的产品管线[43]

PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supportin ...

PONTE VEDRA, Fla., Jan. 31, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, cited today a recent peer-reviewed article in the Journal of the American College of Cardiology (JACC) titled, "When Direct Oral Anticoagulants Should Not Be Standard Treatment" by Antoine Bejjani, MD, et.al. The article examines the numerous medical conditions where dir ...

PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo, M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of Research at H.C. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 88-0860746 (State or other jurisdicti ...

Tecarfarin研发与临床试验 - Tecarfarin是一种口服抗凝血剂，通过小分子药物设计过程，针对不同于治疗血栓和房颤的常用药物的途径[100] - Tecarfarin已在11项人类临床试验中进行评估，包括8项I期试验、2项II期试验和1项II/III期试验[114] - Tecarfarin在II/III期试验中表现出良好的耐受性，只有1.6%的盲目使用Tecarfarin的受试者出现重大出血，没有血栓事件[115] 公司财务状况 - 2023年6月30日的三个月内，公司的总营业费用为1,026,177美元，较2022年同期的482,347美元增长了113.5%[122] - 2023年6月30日的三个月内，公司的研发费用为240,957美元，较2022年同期的202,235美元增长了19%[124] - 2023年6月30日的三个月内，公司的净亏损为1,003,001美元，较2022年同期的502,141美元增加了99.8%[122] - 2023年6月30日的三个月内，公司的利息和股息收入为23,176美元[126] - 2023年6月30日的六个月内，公司的总营业费用为5,226,415美元，较2022年同期的652,867美元增长了700.6%[127] - 2023年6月30日的六个月内，公司的研发费用为3,476,274美元，较2022年同期的220,095美元增长了1489.6%[129] - 2023年6月30日的六个月内，公司的净亏损为6,176,574美元，较2022年同期的678,788美元增加了810.7%[127] - 2023年6月30日的六个月内，公司的利息和股息收入为23,176美元[131] - 公司自成立以来一直处于亏损状态，截至2023年6月30日，公司现金约为320万美元，无债务[136] 公司财务报表与会计准则 - 公司计划进行第三阶段临床试验并提交新药申请，预计需要约4500万美元，计划通过股权和债务融资以及潜在的合作关系筹集额外资金[136] - 公司采用美国通用会计准则（GAAP）编制财务报表[141] - 公司对资产收购进行评估，根据资产是否集中在单个可识别资产或类似可识别资产组中来确定是否应将交易视为业务组合或资产收购[142] - 对于资产收购，公司使用成本累积模型确定资产收购的成本，直接交易成本作为资产收购的一部分被确认[144] - 研发费用按发生额支出，包括支付给代表公司进行某些研发活动的其他实体的费用[145] - 公司评估所有协议，以确定这些工具是否具有衍生品或包含符合嵌入式衍生品的特征[146] - 公司衡量授予给员工、顾问和董事的股票奖励的公允价值，并在必要的服务期内确认补偿[147] - 公司使用估计值和假设，影响财务报表中资产和负债的报告金额以及披露的资产和负债，以及报告期间的费用金额[148] - 公司在报告期内没有任何表外安排[149]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 88-0860746 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-41596 CADRENAL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 88-0860746 (State or other jurisdictio ...